NeuroScientific Biopharmaceuticals Ltd is an Australian public company developing novel peptide-based pharmaceutical products that target a number of neurological disorders that have high unmet medical needs.
The Company’s current R&D program is focused on developing a treatment for stroke-related brain injury and dementia / Alzheimer’s disease, and a diagnostic for early-stage Alzheimer’s disease.
Mr Brian Leedman, MBA
Mr Leedman is a marketing and investor relations professional with over 15 years’ experience in the biotechnology industry. Mr Leedman was co-founder of ResApp Health, Oncosil Medical Limited and Biolife Science Limited (acquired by Imugene Limited). Mr Leedman was formerly the WA chairman of AusBiotech, the association of biotechnology companies in Australia.
Mr Stephen Quantrill, GAICD, Ffin, MIEAust, MSAICE
Mr Quantrill has over 20 years’ experience in multifaceted roles in business ownership, corporate advisory and company directorship with extensive experience as a business executive and private equity professional.
Mr Quantrill is currently the executive chairman of McRae Investments Pty Ltd, a West Australian private equity and venture capital company.
Mr Matthew Liddelow, AFAIM, MAICD
Chief Executive Officer, Managing Director
Mr Liddelow has over twelves years of experience in the commercialisation of biotechnology, medical devices and pharmaceuticals for multi-national companies including AstraZeneca.
Dr Anton Uvarov, PhD, MBA
Dr Uvarov has significant experience as an advisor to the healthcare industry with a focus on the biotechnology sector, both domestically and internationally. Dr Uvarov holds a PhD degree in Biochemistry and Medical Genetics from the University of Manitoba, Canada and an MBA degree from the University of Calgary, Canada.
Mr Thomas Spencer, CPA, MAICD
CFO & Company Secretary
Mr Spencer is a CPA with over 15 years experience in financial management across a range of industries including asset management, investment banking, biotechnology, oil and gas, property and mining.